Response to the letter by Langabeer on "Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria".
作者信息
Song Ik-Chan
机构信息
Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea.
出版信息
Blood Res. 2020 Mar;55(1):68. doi: 10.5045/br.2020.55.1.68. Epub 2020 Mar 30.
Abstract
摘要
相似文献
1
Response to the letter by Langabeer on "Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria".
Blood Res. 2020 Mar;55(1):68. doi: 10.5045/br.2020.55.1.68. Epub 2020 Mar 30.
2
Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria.
Blood Res. 2019 Dec;54(4):284-285. doi: 10.5045/br.2019.54.4.284. Epub 2019 Dec 20.
3
The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Hum Pathol. 2008 Jun;39(6):795-810. doi: 10.1016/j.humpath.2008.02.004.
4
JAK2-positive Philadelphia-negative myeloproliferative neoplasms.
Indian J Pathol Microbiol. 2011 Jan-Mar;54(1):117-20. doi: 10.4103/0377-4929.77355.
5
The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Rom J Intern Med. 2011;49(1):25-30.
6
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Leukemia. 2008 Jan;22(1):14-22. doi: 10.1038/sj.leu.2404955. Epub 2007 Sep 20.
7
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. doi: 10.1055/s-2006-942754.
8
The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Cancer. 2009 Sep 1;115(17):3842-7. doi: 10.1002/cncr.24440.
9
Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis.
Expert Opin Investig Drugs. 2013 Dec;22(12):1603-11. doi: 10.1517/13543784.2013.832199. Epub 2013 Sep 25.
10
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y.
本文引用的文献
1
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
J Stroke Cerebrovasc Dis. 2018 Oct;27(10):2572-2578. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.052. Epub 2018 Jul 26.
2
JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Mayo Clin Proc. 2008 Apr;83(4):457-9. doi: 10.4065/83.4.457.
3
JAK2(V617F): Prevalence in a large Chinese hospital population.
Blood. 2007 Jan 1;109(1):339-42. doi: 10.1182/blood-2006-03-009472. Epub 2006 Aug 31.
Zotero 插件